Suda Pharmaceuticals Ltdの浮動株式数
Suda Pharmaceuticals Ltdの浮動株式数は何ですか。
Suda Pharmaceuticals Ltdの浮動株式数は421.155M 109.49%です。
浮動株式数の定義は何ですか。
浮動株式数は、ロックインされた株式とは対照的に、公的投資家の手にある企業の株式の一部です。
Shares float represents the portion of shares of a corporation that are in the hands of public investors as opposed to locked-in stock held by promoters, company officers, controlling-interest investors, or government. This number is sometimes seen as a better way of calculating market capitalization because it provides a more accurate reflection of what public investors consider the company to be worth. In this context, the float may refer to all the shares outstanding that can be publicly traded
The float is calculated by subtracting the locked-in shares from outstanding shares. Stocks with smaller floats tend to be more volatile than those with larger floats. In general, the large holdings of founding shareholders, corporate cross-holdings, and government holdings in partially privatized companies are excluded when calculating the size of a public float.
ASXのセクタHealth Careにおける浮動株式数の企業と比べるSuda Pharmaceuticals Ltd
Suda Pharmaceuticals Ltdは何をしますか。
Suda Pharmaceuticals Ltd engages in the development of drug delivery technology in Australia, India, Europe and Korea. It offers ZolpiMist, an oro-mucosal spray formulation of zolpidem tartrate marketed under the brand name of Ambien or Stilnox, a non-benzodiazepine prescribed for the short-term treatment of insomnia. The company's product pipeline includes Sumatriptan, an oral spray formulation for the treatment of acute migraine; and anagrelide, a platelet lowering agent for use in thrombosis, which is used for the treatment of cancer. Suda Pharmaceuticals Ltd has license and supply agreement with Teva Pharmaceuticals International GmbH and Mitsubishi Tanabe Pharma Singapore for ZolpiMist oral spray; product development, licence, and supply agreement with Cann Pharmaceutical Australia Ltd for the development of novel oral spray of pharmaceutical-grade cannabinoid derivatives for the treatment of drug resistant epilepsy, melanoma, and motion sickness; and feasibility and option agreement with Zelira Therapeutics for the use of cannabinoids for a range of uses, including insomnia, autism, opioid reduction, anxiety, pain, and cancer. The company also has a feasibility study and option agreement with Laboratorios Ordesa, S.L. The company was formerly known as Suda Limited and changed its name to Suda Pharmaceuticals Ltd in November 2017. Suda Pharmaceuticals Ltd was incorporated in 1999 and is headquartered in Osborne Park, Australia.
Suda Pharmaceuticals Ltdと類似の浮動株式数
- Base Resourcesの浮動株式数は420.154M 35.67%です。
- Intraの浮動株式数は420.491M 92.24%です。
- IMSの浮動株式数は420.500M 42.05%です。
- Huarchi Globalの浮動株式数は420.580M 21.03%です。
- Clean Power Capitalの浮動株式数は420.661M 94.27%です。
- AbraPlata Resourceの浮動株式数は421.006M 91.77%です。
- Suda Pharmaceuticals Ltdの浮動株式数は421.155M 109.49%です。
- MSM Internationalの浮動株式数は421.544M 50.04%です。
- New World Department Store Chinaの浮動株式数は421.570M 25.00%です。
- Fountain Set ()の浮動株式数は422.059M 34.45%です。
- SBI Life Insuranceの浮動株式数は422.069M 42.17%です。
- Bioconの浮動株式数は422.508M 35.21%です。
- Kier Plcの浮動株式数は422.684M 94.71%です。